Abstract
Atherosclerotic cardiovascular diseases (ASCVD) are preferential targets of preventive medicine partially through therapies to improve atherogenic lipid profiles. The aim of the present work was to test a novel nutraceutical formulation (CSN) for its potential effects on plasma triglyceride levels of healthy subjects with moderate dyslipidemia. A cohort of 52 individuals were administered daily, for 8 weeks, with four gastro-resistant capsules of CSN, each one containing 500 mg of cryo-micronized chia seeds and 15 mg of vitamin E, according to a single centre, randomized, placebo controlled, 16 weeks trial. Data showed the following mean lipid changes: triglycerides, −27.5% (P = .0095); total cholesterol, −8.0% (P = .0019); High Density Lipoprotein cholesterol, +5.7% (P = .0042); Low Density Lipoprotein cholesterol, −10.2% (P = .0021). CSN may be regarded as a novel complementary and/or alternative safe remedy with clinical relevance in the primary cardiovascular disease prevention.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call